ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
BeOne Medicines Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$370.17+1.11 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $557.24B
- P/E (TTM)
- 860.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
87.5%+10.4 pts over 5 years
Operating margin
8.4%+545.1 pts over 5 years
Net margin
5.4%+531.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +40.2% | +55.7% | +76.8% | +89.8% | |
| Gross profit | +45.3% | +60.6% | +81.4% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -94.9% | -67.3% | 7.5% | |
| Return on assets | -45.6% | -45.1% | 4.1% | |
| Current ratio | 10.68 | 4.61 | 3.41 | |
| Debt to equity | 0.05 | 0.22 | 0.24 | |
| Net debt to EBITDA | 0.61× | 0.33× | -5.98× | |
| Interest coverage | – | -90.5× | 7.7× | |
| Inventory turnover | – | 1.2× | 1.2× | |
| Capex to revenue | 2196.4% | 38.0% | 3.5% | |
| Diluted shares | 404M | 1.09B | 1.47B |
Where the cash went
Fiscal 2021 to 2025, five years combined
BeOne Medicines generated $5.22B from operations and spent $1.83B on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$5.22B
Used
$1.83B
Capital expenditure$1.83B100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin5.4%
×Asset turnover0.76×
×Equity multiplier1.83×
=Return on equity, FY20257.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 5.4% | 0.76× | 1.83× | 7.5% |
| FY2024 | -16.9% | 0.65× | 1.71× | -18.8% |
| FY2023 | -35.9% | 0.40× | 1.54× | -22.3% |
| FY2022 | -141.5% | 0.19× | 1.42× | -38.1% |
| FY2021 | -123.9% | 0.17× | 1.41× | -29.2% |
| FY2020 | -526.1% | 0.09× | 1.49× | -67.3% |
| FY2019 | -221.5% | 0.22× | 1.43× | -70.2% |
| FY2018 | -339.9% | 0.12× | 1.37× | -55.9% |
| FY2017 | -39.1% | 0.33× | 1.42× | -18.2% |
| FY2016 | -11141.8% | 0.00× | 2.08× | -94.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$286.93M
- Cash generatingOperating cash flow above zero$1.13B
- Return on assets improvedROA up on the prior year-11.1% → 4.8%
- Earnings backed by cashOperating cash flow above net income$1.13B vs $286.93M
- Less leverageLong-term debt to assets fell2.8% → 11.7%
- Better liquidityCurrent ratio rose1.80 → 3.41
- No dilutionShare count did not rise1.37B → 1.47B
- Gross margin improvedGross margin up on the prior year84.41% → 87.49%
- More efficientAsset turnover rose0.66 → 0.90